Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -139.10 KRW | -107.94% |
| 2022 | 1751.18 KRW | 22.83% |
| 2021 | 1425.73 KRW | 20.47% |
| 2020 | 1183.47 KRW | 9.96% |
| 2019 | 1076.32 KRW | 500.12% |
| 2018 | -269.00 KRW | -178.2% |
| 2017 | 344.00 KRW | 7.17% |
| 2016 | 321.00 KRW | 58.13% |
| 2015 | 203.00 KRW | 131.52% |
| 2014 | -644.00 KRW | -376.39% |
| 2013 | 233.00 KRW | 90.98% |
| 2012 | 122.00 KRW | 46.99% |
| 2011 | 83.00 KRW | -44.3% |
| 2010 | 149.00 KRW | 92.81% |
| 2009 | 77.28 KRW | 106.66% |
| 2008 | -1160.17 KRW | -1788.99% |
| 2007 | 68.69 KRW | -69.75% |
| 2006 | 227.07 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 60.42 KRW | -45.83% |
| 2024 Q1 | 112.61 KRW | 127.42% |
| 2023 Q4 | -410.62 KRW | -252.72% |
| 2023 Q1 | 161.15 KRW | -13.83% |
| 2023 Q3 | 268.87 KRW | 266.52% |
| 2023 Q2 | -161.46 KRW | -200.19% |
| 2023 FY | - KRW | -107.94% |
| 2022 Q1 | 533.51 KRW | 46.87% |
| 2022 FY | - KRW | 22.83% |
| 2022 Q4 | 187.02 KRW | -70.56% |
| 2022 Q3 | 635.24 KRW | 60.86% |
| 2022 Q2 | 394.90 KRW | -25.98% |
| 2021 Q2 | 170.00 KRW | 672.73% |
| 2021 Q1 | 22.00 KRW | -88.57% |
| 2021 FY | - KRW | 20.47% |
| 2021 Q4 | 363.26 KRW | -14.33% |
| 2021 Q3 | 424.00 KRW | 149.41% |
| 2020 Q2 | 133.00 KRW | -24.86% |
| 2020 Q4 | 192.41 KRW | -28.47% |
| 2020 Q3 | 269.00 KRW | 102.26% |
| 2020 Q1 | 177.00 KRW | 182762.54% |
| 2020 FY | - KRW | 9.96% |
| 2019 Q1 | 260.00 KRW | 150.72% |
| 2019 FY | - KRW | 500.12% |
| 2019 Q4 | -0.10 KRW | -100.05% |
| 2019 Q3 | 210.00 KRW | 165.82% |
| 2019 Q2 | 79.00 KRW | -69.62% |
| 2018 Q1 | 256.00 KRW | 1.6% |
| 2018 FY | - KRW | -178.2% |
| 2018 Q2 | 96.00 KRW | -62.5% |
| 2018 Q3 | -110.00 KRW | -214.58% |
| 2018 Q4 | -512.62 KRW | -366.02% |
| 2017 Q3 | -35.45 KRW | -126.86% |
| 2017 FY | - KRW | 7.17% |
| 2017 Q1 | 98.00 KRW | -26.4% |
| 2017 Q2 | 132.00 KRW | 34.69% |
| 2017 Q4 | 251.97 KRW | 810.78% |
| 2016 Q3 | 62.00 KRW | -25.3% |
| 2016 Q4 | 133.16 KRW | 114.77% |
| 2016 Q1 | 226.00 KRW | 0.0% |
| 2016 Q2 | 83.00 KRW | -63.27% |
| 2016 FY | - KRW | 58.13% |
| 2015 Q3 | -122.00 KRW | -152.14% |
| 2015 Q1 | 105.36 KRW | 154.98% |
| 2015 FY | - KRW | 131.52% |
| 2015 Q2 | 234.00 KRW | 122.1% |
| 2014 Q2 | -241.76 KRW | -260.63% |
| 2014 Q1 | 150.51 KRW | 318.08% |
| 2014 FY | - KRW | -376.39% |
| 2014 Q4 | -191.63 KRW | 25.72% |
| 2014 Q3 | -258.00 KRW | -6.72% |
| 2013 FY | - KRW | 90.98% |
| 2013 Q1 | 71.58 KRW | 922.57% |
| 2013 Q2 | 22.00 KRW | -69.27% |
| 2013 Q3 | 23.00 KRW | 4.55% |
| 2013 Q4 | 36.00 KRW | 56.52% |
| 2012 Q1 | 39.52 KRW | 558.67% |
| 2012 Q2 | 12.00 KRW | -69.64% |
| 2012 Q3 | 31.00 KRW | 158.33% |
| 2012 FY | - KRW | 46.99% |
| 2012 Q4 | 7.00 KRW | -77.42% |
| 2011 Q2 | 11.00 KRW | -82.57% |
| 2011 Q1 | 63.12 KRW | 128.12% |
| 2011 FY | - KRW | -44.3% |
| 2011 Q4 | 6.00 KRW | -77.78% |
| 2011 Q3 | 27.00 KRW | 145.45% |
| 2010 Q3 | 5.72 KRW | -87.24% |
| 2010 Q1 | 61.06 KRW | 1498.43% |
| 2010 FY | - KRW | 92.81% |
| 2010 Q2 | 44.84 KRW | -26.56% |
| 2010 Q4 | 27.67 KRW | 383.74% |
| 2009 Q1 | -573.76 KRW | -656.83% |
| 2009 FY | - KRW | 106.66% |
| 2009 Q4 | 3.82 KRW | -42.81% |
| 2009 Q3 | 6.68 KRW | 16.78% |
| 2009 Q2 | 5.72 KRW | 101.0% |
| 2008 Q4 | 103.04 KRW | 137.11% |
| 2008 FY | - KRW | -1788.99% |
| 2008 Q3 | -277.64 KRW | 33.1% |
| 2008 Q2 | -415.03 KRW | -966.09% |
| 2008 Q1 | -38.93 KRW | -252.19% |
| 2007 Q2 | 37.50 KRW | 0.0% |
| 2007 Q4 | 25.58 KRW | -46.37% |
| 2007 FY | - KRW | -69.75% |
| 2007 Q3 | 47.70 KRW | 27.2% |
| 2006 FY | - KRW | 0.0% |